<topic id="SUPERDRUG2" outputclass="drug" rev="1.11">
  <title>SUPERDRUG ETHINYLESTRADIOL WITH ETONOGESTREL</title>
  <body>
    <data name="doi">doi:10.18578/BNF_778077044</data>
    <p outputclass="interactionsLinks"> List of individual interactants: <xref format="dita" href="bnf_int_783.xml">Ibuprofen</xref></p>
    <p outputclass="constituentDrugs">The properties listed below are those particular to the combination only. For the properties of the components please consider, <xref format="dita" href="PHP4479.xml">ethinylestradiol</xref>, <xref format="dita" href="PHP97243.xml">etonogestrel</xref>.</p>
    <data name="vtmid">38268001</data>
    <data name="classifications">
      <data name="classification">
        <data name="drugClassification">_322611837</data>
      </data>
    </data>
    <data name="primaryDomainOfEffect">
      <data name="domainOfEffect"> musculoskeletal system   </data>
    </data>
    <data name="secondaryDomainsOfEffect">
      <data name="domainOfEffect"> cardiovascular system  </data>
      <data name="domainOfEffect"> genito-urinary system  </data>
      <data name="domainOfEffect"> nervous system   </data>
    </data>
    <p outputclass="synonyms">
      <b>Superdrug</b>
      <b>Ethinylestradiol</b>
      <b>Etonogestrel</b>
    </p>
  </body>
  <topic id="PHP42396" outputclass="drugAction" rev="1.39">
    <title>Drug action</title>
    <body>
      <section>
        <sectiondiv>
          <p>The glycopeptide antibiotic vancomycin has bactericidal activity against aerobic and anaerobic Gram-positive bacteria including multi-resistant staphylococci. However, there are reports of <ph outputclass="organism"><i>Staphylococcus aureus</i></ph> with reduced susceptibility to glycopeptides. There are increasing reports of glycopeptide-resistant enterococci. Penetration into cerebrospinal fluid is poor.</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">intravenous</ph> use</p>
          <p>Vancomycin has a long duration of action and can therefore be given every 12 hours.</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">oral</ph> use</p>
          <p>An imidazole derivative which acts as a potent inhibitor of cortisol and aldosterone synthesis by inhibiting the activity of 17α-hydroxylase, 11-hydroxylation steps and at higher doses the cholesterol side-chain cleavage enzyme.</p>
          <p>It also inhibits the activity of adrenal C17-20 lyase enzymes resulting in androgen synthesis inhibition, and may have a direct effect on corticotropic tumour cells in patients with Cushing's disease.</p>
        </sectiondiv>
      </section>
    </body>
  </topic>
  <topic id="PHP47421" outputclass="indicationsAndDose" rev="1.53">
    <title>Indications and dose</title>
    <body>
      <section outputclass="indicationAndDoseGroup">
        <sectiondiv outputclass="therapeuticIndications">
          <p outputclass="therapeuticIndication">Treatment of focal spasticity (including hand and wrist disability associated with stroke) (specialist use only)</p>
          <p outputclass="therapeuticIndication">Blepharospasm (specialist use only)</p>
          <p outputclass="therapeuticIndication">Hemifacial spasm (specialist use only)</p>
          <p outputclass="therapeuticIndication">Spasmodic torticollis (specialist use only)</p>
          <p outputclass="therapeuticIndication">Severe hyperhidrosis of the axillae (specialist use only)</p>
          <p outputclass="therapeuticIndication">Prophylaxis of headaches in adults with chronic migraine (specialist use only)</p>
          <p outputclass="therapeuticIndication">Temporary improvement of moderate to severe wrinkles between the eyebrows in adults under 65 years (specialist use only)</p>
          <p outputclass="therapeuticIndication">Ankle disability due to lower limb spasticity associated with stroke (specialist use only)</p>
          <p outputclass="therapeuticIndication">Management of bladder dysfunctions (specialist use only)</p>
          <p outputclass="therapeuticIndication">Temporary improvement of moderate to severe crow's feet (specialist use only)</p>
        </sectiondiv>
        <p outputclass="routesOfAdministration">By subcutaneous injection, or by intradermal injection, or by intramuscular injection</p>
        <ul outputclass="patientGroups">
          <li outputclass="patientGroup adult">
            <p>Adult</p>
            <p>(consult product literature).</p>
          </li>
        </ul>
      </section>
      <section outputclass="indicationAndDoseGroup">
        <sectiondiv outputclass="therapeuticIndications">
          <p outputclass="therapeuticIndication">Pain and inflammation in rheumatic disease and other musculoskeletal disorders</p>
          <p outputclass="therapeuticIndication">Mild to moderate pain including dysmenorrhoea</p>
          <p outputclass="therapeuticIndication">Postoperative analgesia</p>
          <p outputclass="therapeuticIndication">Migraine</p>
          <p outputclass="therapeuticIndication">Dental pain</p>
        </sectiondiv>
        <p outputclass="routesOfAdministration">By mouth using immediate-release medicines</p>
        <ul outputclass="patientGroups">
          <li outputclass="patientGroup adult">
            <p>Adult</p>
            <p>Initially 300–400 mg 3–4 times a day; increased if necessary up to 600 mg 4 times a day; maintenance 200–400 mg 3 times a day, may be adequate.</p>
          </li>
        </ul>
        <p outputclass="routesOfAdministration">By mouth using modified-release medicines</p>
        <ul outputclass="patientGroups">
          <li outputclass="patientGroup adult">
            <p>Adult</p>
            <p>1.6 g once daily, dose to be taken in the early evening, increased if necessary to 2.4 g daily in 2 divided doses, dose to be increased only in severe cases.</p>
          </li>
        </ul>
      </section>
      <section outputclass="indicationAndDoseGroup">
        <sectiondiv outputclass="therapeuticIndications">
          <p outputclass="therapeuticIndication">
            <ph outputclass="organism">
              <i>
                <i>Clostridium difficile</i>
              </i>
            </ph> infection</p>
        </sectiondiv>
        <p outputclass="routesOfAdministration">By mouth</p>
        <ul outputclass="patientGroups">
          <li outputclass="patientGroup adult">
            <p>Adult</p>
            <p>125 mg 4 times a day for 10–14 days, dose may be increased if infection fails to respond or is life-threatening, increased if necessary up to 500 mg 4 times a day.</p>
          </li>
        </ul>
      </section>
      <section outputclass="indicationAndDoseGroup">
        <sectiondiv outputclass="therapeuticIndications">
          <p outputclass="therapeuticIndication">Mild to moderate pain</p>
          <p outputclass="therapeuticIndication">Pain and inflammation of soft-tissue injuries</p>
          <p outputclass="therapeuticIndication">Pyrexia with discomfort</p>
        </sectiondiv>
        <p outputclass="routesOfAdministration">Initially by mouth using immediate-release medicines</p>
        <ul outputclass="patientGroups">
          <li outputclass="patientGroup child">
            <p>Child 3–5 months</p>
            <p>50 mg 3 times a day, maximum daily dose to be given in 3–4 divided doses; maximum 30 mg/kg per day.</p>
          </li>
          <li outputclass="patientGroup child">
            <p>Child 6–11 months</p>
            <p>50 mg 3–4 times a day, maximum daily dose to be given in 3–4 divided doses; maximum 30 mg/kg per day.</p>
          </li>
          <li outputclass="patientGroup child">
            <p>Child 1–3 years</p>
            <p>100 mg 3 times a day, maximum daily dose to be given in 3–4 divided doses; maximum 30 mg/kg per day.</p>
          </li>
          <li outputclass="patientGroup child">
            <p>Child 4–6 years</p>
            <p>150 mg 3 times a day, maximum daily dose to be given in 3–4 divided doses; maximum 30 mg/kg per day.</p>
          </li>
          <li outputclass="patientGroup child">
            <p>Child 7–9 years</p>
            <p>200 mg 3 times a day, maximum daily dose to be given in 3–4 divided doses; maximum 30 mg/kg per day; maximum 2.4 g per day.</p>
          </li>
          <li outputclass="patientGroup child">
            <p>Child 10–11 years</p>
            <p>300 mg 3 times a day, maximum daily dose to be given in 3–4 divided doses; maximum 30 mg/kg per day; maximum 2.4 g per day.</p>
          </li>
          <li outputclass="patientGroup child">
            <p>Child 12–17 years</p>
            <p>Initially 300–400 mg 3–4 times a day; (by mouth using immediate-release medicines) increased if necessary up to 600 mg 4 times a day; (by mouth) maintenance 200–400 mg 3 times a day, may be adequate.</p>
          </li>
        </ul>
      </section>
      <section outputclass="indicationAndDoseGroup">
        <sectiondiv outputclass="therapeuticIndications">
          <p outputclass="therapeuticIndication">Pain and inflammation</p>
        </sectiondiv>
        <p outputclass="routesOfAdministration">By mouth using modified-release medicines</p>
        <ul outputclass="patientGroups">
          <li outputclass="patientGroup child">
            <p>Child 12–17 years</p>
            <p>1.6 g once daily, dose preferably taken in the early evening, increased to 2.4 g daily in 2 divided doses, dose to be increased only in severe cases.</p>
          </li>
        </ul>
      </section>
      <section outputclass="indicationAndDoseGroup">
        <sectiondiv outputclass="therapeuticIndications">
          <p outputclass="therapeuticIndication">Pain and inflammation in rheumatic disease including juvenile idiopathic arthritis</p>
        </sectiondiv>
        <p outputclass="routesOfAdministration">By mouth using immediate-release medicines</p>
        <ul outputclass="patientGroups">
          <li outputclass="patientGroup child">
            <p>Child 3 months–17 years</p>
            <p>30–40 mg/kg daily in 3–4 divided doses; maximum 2.4 g per day.</p>
          </li>
        </ul>
      </section>
      <section outputclass="indicationAndDoseGroup">
        <sectiondiv outputclass="therapeuticIndications">
          <p outputclass="therapeuticIndication">Pain and inflammation in systemic juvenile idiopathic arthritis</p>
        </sectiondiv>
        <p outputclass="routesOfAdministration">By mouth using immediate-release medicines</p>
        <ul outputclass="patientGroups">
          <li outputclass="patientGroup child">
            <p>Child 3 months–17 years</p>
            <p>Up to 60 mg/kg daily in 4–6 divided doses; maximum 2.4 g per day.</p>
          </li>
        </ul>
      </section>
      <section outputclass="indicationAndDoseGroup">
        <sectiondiv outputclass="therapeuticIndications">
          <p outputclass="therapeuticIndication">Post-immunisation pyrexia in infants (on doctor’s advice only)</p>
        </sectiondiv>
        <p outputclass="routesOfAdministration">By mouth using immediate-release medicines</p>
        <ul outputclass="patientGroups">
          <li outputclass="patientGroup child">
            <p>Child 2–3 months</p>
            <p>50 mg for 1 dose, followed by 50 mg after 6 hours if required.</p>
          </li>
          <li outputclass="patientGroup neonate">
            <p>Neonate</p>
            <p>50 mg for 1 dose, followed by 50 mg after 6 hours if required.</p>
          </li>
        </ul>
      </section>
      <section outputclass="indicationAndDoseGroup">
        <sectiondiv outputclass="therapeuticIndications">
          <p outputclass="therapeuticIndication">Pain relief in musculoskeletal conditions</p>
          <p outputclass="therapeuticIndication">Treatment in knee or hand osteoarthritis (adjunct)</p>
        </sectiondiv>
        <p outputclass="routesOfAdministration">To the skin</p>
        <ul outputclass="patientGroups">
          <li outputclass="patientGroup adult">
            <p>Adult</p>
            <p>Apply up to 3 times a day, ibuprofen gel 5% gel to be administered.</p>
          </li>
          <li outputclass="patientGroup adult female">
            <p>Adult (Female patients)</p>
            <p>Apply up to 3 times a day, ibuprofen gel 5% gel to be administered.</p>
          </li>
          <li outputclass="patientGroup adult male">
            <p>Adult (Male patients)</p>
            <p>Apply up to 3 times a day, ibuprofen gel 5% gel to be administered.</p>
          </li>
        </ul>
      </section>
      <section outputclass="indicationAndDoseGroup">
        <sectiondiv outputclass="therapeuticIndications">
          <p outputclass="therapeuticIndication">Primary hypercholesterolaemia (type IIa including heterozygous familial hypercholesterolaemia), mixed dyslipidaemia (type IIb), or homozygous familial hypercholesterolaemia in patients who have not responded adequately to diet and other appropriate measures</p>
        </sectiondiv>
        <p outputclass="routesOfAdministration">By mouth</p>
        <ul outputclass="patientGroups">
          <li outputclass="patientGroup adult">
            <p>Adult 18–69 years</p>
            <p>Initially 5–10 mg once daily, then increased if necessary to 20 mg once daily, dose to be increased at intervals of at least 4 weeks.</p>
          </li>
          <li outputclass="patientGroup adult asian">
            <p>Adult (patients of Asian origin)</p>
            <p>Initially 5 mg once daily, then increased if necessary up to 20 mg once daily, dose to be increased at intervals of at least 4 weeks.</p>
          </li>
          <li outputclass="patientGroup adult eastAsian">
            <p>Adult (patients of East Asian origin)</p>
            <p>Initially 5 mg once daily, then increased if necessary up to 20 mg once daily, dose to be increased at intervals of at least 4 weeks.</p>
          </li>
        </ul>
      </section>
      <section outputclass="indicationAndDoseGroup">
        <sectiondiv outputclass="therapeuticIndications">
          <p outputclass="therapeuticIndication">Primary hypercholesterolaemia (type IIa including heterozygous familial hypercholesterolaemia), mixed dyslipidaemia (type IIb), or homozygous familial hypercholesterolaemia in patients who have not responded adequately to diet and other appropriate measures and who have risk factors for myopathy or rhabdomyolysis</p>
        </sectiondiv>
        <p outputclass="routesOfAdministration">By mouth</p>
        <ul outputclass="patientGroups">
          <li outputclass="patientGroup adult">
            <p>Adult</p>
            <p>Initially 5 mg once daily, then increased if necessary up to 20 mg once daily, dose to be increased at intervals of at least 4 weeks.</p>
          </li>
        </ul>
      </section>
      <section outputclass="indicationAndDoseGroup">
        <sectiondiv outputclass="therapeuticIndications">
          <p outputclass="therapeuticIndication">Prevention of cardiovascular events in patients at high risk of a first cardiovascular event and with risk factors for myopathy or rhabdomyolysis</p>
        </sectiondiv>
        <p outputclass="routesOfAdministration">By mouth</p>
        <ul outputclass="patientGroups">
          <li outputclass="patientGroup adult">
            <p>Adult</p>
            <p>Initially 5 mg once daily, then increased if necessary up to 20 mg once daily.</p>
          </li>
        </ul>
      </section>
      <section outputclass="potency">
        <title>Potency</title>
        <p>Hydrocortisone cream and ointment 0.5 to 2.5%: mild</p>
      </section>
      <section outputclass="pharmacokinetics">
        <title>Pharmacokinetics</title>
        <p>Vancomycin should <b>not</b> be given by mouth for systemic infections because it is not absorbed significantly.</p>
      </section>
      <section outputclass="doseEquivalence">
        <title>Dose equivalence and conversion</title>
        <p>480 mg of co-trimoxazole consists of sulfamethoxazole 400 mg and trimethoprim 80 mg. </p>
      </section>
      <sectiondiv>
        <p>Initially 5 mg once daily with concomitant fibrate increased if necessary to max. 20 mg daily. For dose adjustments with concomitant atazanavir, clopidogrel, darunavir, dronedarone, eltrombopag, ezetimibe, itraconazole, lopinavir, or tipranavir, consult product literature.</p>
      </sectiondiv>
      <section outputclass="doseAdjustments">
        <title>Dose adjustments due to interactions</title>
        <sectiondiv>
          <p>Max. 1 <i>Vesomni</i><tm tmtype="reg" /> tablet daily with concomitant potent inhibitors of cytochrome P450 enzyme CYP3A4 (such as itraconazole, ketoconazole, or ritonavir).</p>
        </sectiondiv>
      </section>
      <section outputclass="extremesOfBodyWeight">
        <title>Doses at extremes of body-weight</title>
        <p>To avoid excessive dosage in obese patients, dose may need to be calculated on the basis of ideal bodyweight.</p>
      </section>
    </body>
  </topic>
  <topic id="PHP87039" outputclass="directionsForAdministration" rev="1.19">
    <title>Directions for administration</title>
    <body>
      <section>
        <sectiondiv>
          <p outputclass="title">Changing method of contraception to vaginal ring</p>
          <p>Insert ring at the latest on the day after the usual tablet-free, patch-free, or inactive-tablet interval. If previous contraceptive used correctly, or pregnancy can reasonably be excluded, can switch to ring on any day of cycle.</p>
          <sectiondiv>
            <p outputclass="title">Changing from progestogen-only method</p>
            <p>From an implant or intra-uterine progestogen-only device, insert ring on the day implant or intra-uterine progestogen-only device removed; from an injection, insert ring when next injection due; from oral preparation, first ring may be inserted on any day after stopping pill. For all methods additional precautions (barrier methods) should be used concurrently for first 7 days.</p>
          </sectiondiv>
          <sectiondiv>
            <p outputclass="specificity">With <ph outputclass="route">intravenous</ph> use in neonates</p>
            <p>For <i>slow intravenous injection</i>, give over 15 minutes, preferably undiluted. May be diluted with Glucose 5% <i>or</i> Sodium Chloride 0.9%.</p>
          </sectiondiv>
          <sectiondiv>
            <p outputclass="specificity">With <ph outputclass="route">topical</ph> use in adults</p>
            <p>For topical preparations, apply with gentle massage only.</p>
          </sectiondiv>
        </sectiondiv>
      </section>
    </body>
  </topic>
  <topic id="PHP73139" outputclass="importantSafetyInformation" rev="1.17">
    <title>Important safety information</title>
    <body>
      <section>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">intra-uterine</ph> use</p>
          <p outputclass="title">MHRA/CHM advice (June 2015) Intra-uterine contraception: uterine perforation—updated information on risk factors</p>
          <p>Uterine perforation most often occurs during insertion, but might not be detected until sometime later. The risk of uterine perforation is increased when the device is inserted up to 36 weeks postpartum or in patients who are breastfeeding. Before inserting an intra-uterine contraceptive device, inform patients that perforation occurs in approximately 1 in every 1000 insertions and signs and symptoms include:</p>
          <ul>
            <li>severe pelvic pain after insertion (worse than period cramps);</li>
            <li>pain or increased bleeding after insertion which continues for more than a few weeks;</li>
            <li>sudden changes in periods;</li>
            <li>pain during intercourse;</li>
            <li>unable to feel the threads.</li>
          </ul>
          <p>Patients should be informed on how to check their threads and to arrange a check-up if threads cannot be felt, especially if they also have significant pain. Partial perforation may occur even if the threads can be seen; consider this if there is severe pain following insertion and perform an ultrasound.</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="title">Restrictions on the use of co-trimoxazole</p>
          <p>Co-trimoxazole is the drug of choice in the prophylaxis and treatment of <ph outputclass="organism"><i>Pneumocystis jirovecii</i></ph> (<ph outputclass="organism"><i>Pneumocystis carinii</i></ph>) pneumonia; it is also indicated for nocardiasis, <ph outputclass="organism"><i>Stenotrophomonas maltophilia</i></ph> infection [unlicensed indication], and toxoplasmosis. It should only be considered for use in acute exacerbations of chronic bronchitis and infections of the urinary tract when there is bacteriological evidence of sensitivity to co-trimoxazole and good reason to prefer this combination to a single antibacterial; similarly it should only be used in acute otitis media in children when there is good reason to prefer it. Co-trimoxazole is also used for the treatment of infections caused by <ph outputclass="organism"><i>Burkholderia cepacia</i></ph> in cystic fibrosis [unlicensed indication].</p>
        </sectiondiv>
      </section>
    </body>
  </topic>
  <topic id="PHP47320" outputclass="unlicensedUse" rev="1.21">
    <title>Unlicensed use</title>
    <body>
      <section>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">intravenous</ph> use in neonates</p>
          <p>Orphan licence for the injection for closure of ductus arteriosus in premature neonates less than 34 weeks corrected gestational age.</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">oral</ph> use in children</p>
          <p>Not licensed for use in children under 3 months or body-weight under 5 kg.</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">oral</ph> use in children</p>
          <p>Maximum dose for systemic juvenile idiopathic arthritis is unlicensed.</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">oral</ph> use in children</p>
          <p>Not licensed for typhoid fever, Lyme disease, chronic <ph outputclass="organism"><i>Pseudomonas aeruginosa</i></ph> infection in cystic fibrosis, or prophylaxis of group A streptococcal infection.</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">oral</ph> use in adults</p>
          <p>Oral azithromycin not licensed for trachoma which results from chronic infection with <ph outputclass="organism"><i>Chlamydia trachomatis</i></ph>.</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">intravenous</ph> use or <ph outputclass="route">oral</ph> use in adults</p>
          <p>Not licensed for uncomplicated gonorrhoea, mild or moderate typhoid due to multiple-antibacterial-resistant organisms, Lyme disease, or prophylaxis of group A streptococcal infection.</p>
          <p>Not licensed for community-acquired pneumonia (high severity) when oral treatment continues for more than 3 days.</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">intravenous</ph> use for <ph outputclass="indication">acute anaphylaxis</ph> in children</p>
          <p>Auto-injector delivering 150-microgram dose of adrenaline not licensed for use in children body-weight under 15 kg.</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">intravenous</ph> use for <ph outputclass="indication">acute hypotension</ph> in children</p>
          <p>Adrenaline 1 in 1000 (1 mg/mL) solution is not licensed for intravenous administration.</p>
        </sectiondiv>
      </section>
    </body>
  </topic>
  <topic id="PHP54740" outputclass="contraindications" rev="1.8">
    <title>Contra-indications</title>
    <body>
      <section outputclass="contraindications">
        <p>
          <ph outputclass="contraindication">Intestinal obstruction</ph>
        </p>
        <sectiondiv outputclass="additionalContraindications">
          <sectiondiv outputclass="cautionsOrContraindicationsWithRoutes">
            <p outputclass="title">With intravenous use</p>
            <p>
              <ph outputclass="contraindication">active bleeding (especially intracranial or gastro-intestinal)</ph> (in neonates); <ph outputclass="contraindication">coagulation defects</ph> (in neonates); <ph outputclass="contraindication">known or suspected necrotising enterocolitis</ph> (in neonates); <ph outputclass="contraindication">life-threatening infection</ph> (in neonates); <ph outputclass="contraindication">marked unconjugated hyperbilirubinaemia</ph> (in neonates); <ph outputclass="contraindication">pulmonary hypertension</ph> (in neonates); <ph outputclass="contraindication">thrombocytopenia</ph> (in neonates)</p>
          </sectiondiv>
          <sectiondiv outputclass="cautionsOrContraindicationsWithRoutes">
            <p outputclass="title">With oral use</p>
            <p>
              <ph outputclass="contraindication">active gastro-intestinal bleeding</ph> (in children); <ph outputclass="contraindication">active gastro-intestinal ulceration</ph> (in children); <ph outputclass="contraindication">history of gastro-intestinal bleeding related to previous NSAID therapy</ph> (in children); <ph outputclass="contraindication">history of gastro-intestinal perforation related to previous NSAID therapy</ph> (in children); <ph outputclass="contraindication">history of recurrent gastro-intestinal haemorrhage (two or more distinct episodes)</ph> (in children); <ph outputclass="contraindication">history of recurrent gastro-intestinal ulceration (two or more distinct episodes)</ph> (in children); <ph outputclass="contraindication">severe heart failure</ph> (in children)</p>
          </sectiondiv>
          <sectiondiv outputclass="cautionsOrContraindicationsWithRoutes">
            <p outputclass="title">With systemic use</p>
            <p>
              <ph outputclass="contraindication">active gastro-intestinal bleeding</ph> (in adults); <ph outputclass="contraindication">active gastro-intestinal ulceration</ph> (in adults); <ph outputclass="contraindication">history of gastro-intestinal bleeding related to previous NSAID therapy</ph> (in adults); <ph outputclass="contraindication">history of gastro-intestinal perforation related to previous NSAID therapy</ph> (in adults); <ph outputclass="contraindication">history of recurrent gastro-intestinal haemorrhage (two or more distinct episodes)</ph> (in adults); <ph outputclass="contraindication">history of recurrent gastro-intestinal ulceration (two or more distinct episodes)</ph> (in adults); <ph outputclass="contraindication">severe heart failure</ph> (in adults)</p>
          </sectiondiv>
          <sectiondiv outputclass="cautionsOrContraindicationsWithRoutes">
            <p outputclass="title">With intra-uterine use</p>
            <p>
              <ph outputclass="contraindication">active trophoblastic disease (until return to normal of urine- and plasma-gonadotrophin concentration</ph>; <ph outputclass="contraindication">acute cervicitis</ph>; <ph outputclass="contraindication">acute vaginitis</ph>; <ph outputclass="contraindication">distorted uterine cavity</ph>; <ph outputclass="contraindication">established immunosuppression</ph>; <ph outputclass="contraindication">genital malignancy</ph>; <ph outputclass="contraindication">history of breast cancer but can be considered for a woman in long-term remission who has menorrhagia and requires effective contraception</ph>; <ph outputclass="contraindication">infected abortion during the previous three months</ph>; <ph outputclass="contraindication">marked immunosuppression</ph>; <ph outputclass="contraindication">not suitable for emergency contraception</ph>; <ph outputclass="contraindication">pelvic inflammatory disease</ph>; <ph outputclass="contraindication">postpartum endometritis</ph>; <ph outputclass="contraindication">recent sexually transmitted infection (if not fully investigated and treated)</ph>; <ph outputclass="contraindication">severe anaemia</ph>; <ph outputclass="contraindication">small uterine cavity</ph>; <ph outputclass="contraindication">unexplained uterine bleeding</ph></p>
          </sectiondiv>
          <sectiondiv outputclass="cautionsOrContraindicationsWithRoutes">
            <p outputclass="title">With oral use</p>
            <p>
              <ph outputclass="contraindication">
                <xref format="dita" href="PHP78608.xml" type="bookmark">Acute porphyrias</xref>
              </ph>
            </p>
          </sectiondiv>
          <sectiondiv outputclass="cautionsOrContraindicationsWithIndications">
            <p outputclass="title">When used for contraception</p>
            <p>
              <ph outputclass="routesAndIndications">with <ph outputclass="route">oral</ph> use for contraception</ph>
              <ph outputclass="contraindication">history of breast cancer but can be used after 5 years if no evidence of disease and non-hormonal contraceptive methods unacceptable</ph>; <ph outputclass="contraindication">severe arterial disease</ph>; <ph outputclass="contraindication">undiagnosed vaginal bleeding</ph></p>
          </sectiondiv>
        </sectiondiv>
      </section>
      <section outputclass="importantAdvice">
        <title>Contra-indications, further information</title>
        <sectiondiv>
          <p outputclass="specificity">When used by <ph outputclass="route">regional administration</ph></p>
          <p outputclass="title">Injection site</p>
          <p>Local anaesthetics should not be injected into inflamed or infected tissues nor should they be applied to damaged skin. Increased absorption into the blood increases the possibility of systemic side-effects, and the local anaesthetic effect may also be reduced by altered local pH.</p>
        </sectiondiv>
      </section>
    </body>
  </topic>
  <topic id="PHP47574" outputclass="cautions" rev="1.66">
    <title>Cautions</title>
    <body>
      <section outputclass="cautions">
        <p>
          <ph outputclass="caution">
            <xref format="dita" href="PHP78608.xml" type="bookmark">Acute porphyrias</xref>
          </ph>; <ph outputclass="caution">diarrhoea</ph>; <ph outputclass="caution">extreme caution in blood disorders (avoid if severe)</ph>; <ph outputclass="caution">peptic ulceration</ph>; <ph outputclass="caution">photosensitivity—psoriasis lesions aggravated by UV radiation (skin ulceration reported)</ph>; <ph outputclass="caution">risk of accumulation in pleural effusion or ascites— drain before treatment</ph>; <ph outputclass="caution">ulcerative colitis</ph>; <ph outputclass="caution">ulcerative stomatitis</ph></p>
        <sectiondiv outputclass="additionalCautions">
          <sectiondiv outputclass="cautionsOrContraindicationsWithRoutes">
            <p outputclass="title">With intravenous use</p>
            <p>
              <ph outputclass="caution">may mask symptoms of infection</ph> (in neonates)</p>
          </sectiondiv>
          <sectiondiv outputclass="cautionsOrContraindicationsWithRoutes">
            <p outputclass="title">With oral use</p>
            <p>
              <ph outputclass="caution">cardiac impairment (NSAIDs may impair renal function)</ph> (in children); <ph outputclass="caution">cerebrovascular disease</ph> (in children); <ph outputclass="caution">coagulation defects</ph> (in children); <ph outputclass="caution">connective-tissue disorders</ph> (in children); <ph outputclass="caution">Crohn’s disease (may be exacerbated)</ph> (in children); <ph outputclass="caution">heart failure</ph> (in children); <ph outputclass="caution">ischaemic heart disease</ph> (in children); <ph outputclass="caution">peripheral arterial disease</ph> (in children); <ph outputclass="caution">risk factors for cardiovascular events</ph> (in children); <ph outputclass="caution">ulcerative colitis (may be exacerbated)</ph> (in children); <ph outputclass="caution">uncontrolled hypertension</ph> (in children)</p>
          </sectiondiv>
          <sectiondiv outputclass="cautionsOrContraindicationsWithRoutes">
            <p outputclass="title">With systemic use</p>
            <p>
              <ph outputclass="caution">allergic disorders</ph> (in adults); <ph outputclass="caution">cardiac impairment (NSAIDs may impair renal function)</ph> (in adults); <ph outputclass="caution">cerebrovascular disease</ph> (in adults); <ph outputclass="caution">coagulation defects</ph> (in adults); <ph outputclass="caution">connective-tissue disorders</ph> (in adults); <ph outputclass="caution">Crohn’s disease (may be exacerbated)</ph> (in adults); <ph outputclass="caution">elderly (risk of serious side-effects and fatalities)</ph> (in adults); <ph outputclass="caution">heart failure</ph> (in adults); <ph outputclass="caution">ischaemic heart disease</ph> (in adults); <ph outputclass="caution">peripheral arterial disease</ph> (in adults); <ph outputclass="caution">risk factors for cardiovascular events</ph> (in adults); <ph outputclass="caution">ulcerative colitis (may be exacerbated)</ph> (in adults); <ph outputclass="caution">uncontrolled hypertension</ph> (in adults)</p>
          </sectiondiv>
          <sectiondiv outputclass="cautionsOrContraindicationsWithRoutes">
            <p outputclass="title">With topical use</p>
            <p>
              <ph outputclass="caution">avoid contact with eyes</ph> (in adults); <ph outputclass="caution">avoid contact with inflamed or broken skin</ph> (in adults); <ph outputclass="caution">avoid contact with mucous membranes</ph> (in adults); <ph outputclass="caution">not for use with occlusive dressings</ph> (in adults); <ph outputclass="caution">topical application of large amounts can result in systemic effects, including hypersensitivity and asthma (renal disease has also been reported)</ph> (in adults)</p>
          </sectiondiv>
          <sectiondiv outputclass="cautionsOrContraindicationsWithIndications">
            <p outputclass="title">When used for contraception</p>
            <p>
              <ph outputclass="routesAndIndications">with <ph outputclass="route">oral</ph> use for contraception</ph>
              <ph outputclass="caution">active trophoblastic disease (until return to normal of urine- and plasma-gonadotrophin concentration)—seek specialist advice</ph>; <ph outputclass="caution">arterial disease</ph>; <ph outputclass="caution">functional ovarian cysts</ph>; <ph outputclass="caution">history of jaundice in pregnancy</ph>; <ph outputclass="caution">malabsorption syndromes</ph>; <ph outputclass="caution">past ectopic pregnancy</ph>; <ph outputclass="caution">sex-steroid dependent cancer</ph>; <ph outputclass="caution">systemic lupus erythematosus with positive (or unknown) antiphospholipid antibodies</ph></p>
          </sectiondiv>
          <sectiondiv outputclass="cautionsOrContraindicationsWithIndications">
            <p outputclass="title">When used for emergency contraception</p>
            <p>
              <ph outputclass="routesAndIndications">with <ph outputclass="route">oral</ph> use for emergency contraception</ph>
              <ph outputclass="caution">active trophoblastic disease (until return to normal of urine- and plasma-gonadotrophin concentration)—seek specialist advice</ph>; <ph outputclass="caution">past ectopic pregnancy</ph>; <ph outputclass="caution">severe malabsorption syndromes</ph></p>
          </sectiondiv>
        </sectiondiv>
      </section>
      <section outputclass="importantAdvice">
        <title>Cautions, further information</title>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">oral</ph> use</p>
          <p outputclass="title">Use as a contraceptive in co-morbidities</p>
          <p>The product literature advises caution in patients with history of thromboembolism, hypertension, diabetes meillitus and migraine; evidence for caution in these conditions is unsatisfactory.</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="title">High-dose ibuprofen</p>
          <p>A small increase in cardiovascular risk, similar to the risk associated with cyclo-oxygenase-2 inhibitors and diclofenac, has been reported with high-dose ibuprofen (≥ 2.4 g daily); use should be avoided in patients with established ischaemic heart disease, peripheral arterial disease, cerebrovascular disease, congestive heart failure (New York Heart Association classification II-III), and uncontrolled hypertension.</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="title">Risk of infection with intra-uterine devices</p>
          <p>The main excess risk of infection occurs in the first 20 days after insertion and is believed to be related to existing carriage of a sexually transmitted infection. Women are considered to be at a higher risk of sexually transmitted infections if:</p>
          <ul>
            <li>they are under 25 years old <i>or</i></li>
            <li>they are over 25 years old <i>and</i></li>
            <li>have a new partner <i>or</i></li>
            <li>have had more than one partner in the past year <i>or</i></li>
            <li>their regular partner has other partners.</li>
          </ul>
          <p>In these women, pre-insertion screening (for chlamydia and, depending on sexual history and local prevalence of disease, <ph outputclass="organism"><i>Neisseria gonorrhoeae</i></ph>) should be performed. If results are unavailable at the time of fitting an intrauterine device for emergency contraception, appropriate prophylactic antibacterial cover should be given. The woman should be advised to attend <i>as an emergency</i> if she experiences sustained pain during the next 20 days.</p>
          <p>An intra-uterine device should not be removed in mid-cycle unless an additional contraceptive was used for the previous 7 days. If removal is essential post-coital contraception should be considered.</p>
        </sectiondiv>
      </section>
    </body>
  </topic>
  <topic id="PHP47409" outputclass="interactions" rev="1.10">
    <title>Interactions</title>
    <body>
      <section outputclass="general">
        <sectiondiv>
          <p>Appendix 1 (NSAIDs).</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">topical</ph> use in adults</p>
          <p>Interactions do not generally apply to topical NSAIDs.</p>
        </sectiondiv>
      </section>
    </body>
  </topic>
  <topic id="PHP47342" outputclass="sideEffects" rev="1.49">
    <title>Side-effects</title>
    <body>
      <section outputclass="generalSideEffects">
        <title>General side-effects:</title>
        <sectiondiv outputclass="frequencies">
          <sectiondiv outputclass="commonOrVeryCommon">
            <p outputclass="title">Common or very common</p>
            <p outputclass="sideEffects">
              <ph outputclass="sideEffect">Depression (sometimes severe)</ph>; <ph outputclass="sideEffect">headache</ph>; <ph outputclass="sideEffect">nausea</ph></p>
          </sectiondiv>
          <sectiondiv outputclass="uncommon">
            <p outputclass="title">Uncommon</p>
            <p outputclass="sideEffects">
              <ph outputclass="sideEffect">Anorexia</ph>; <ph outputclass="sideEffect">antibiotic-associated colitis</ph>; <ph outputclass="sideEffect">anxiety</ph>; <ph outputclass="sideEffect">blood disorders</ph>; <ph outputclass="sideEffect">convulsions</ph>; <ph outputclass="sideEffect">dry mouth</ph>; <ph outputclass="sideEffect">dysuria</ph>; <ph outputclass="sideEffect">glycosuria</ph>; <ph outputclass="sideEffect">hyperkalaemia</ph>; <ph outputclass="sideEffect">hypoaesthesia</ph>; <ph outputclass="sideEffect">influenza-like symptoms</ph>; <ph outputclass="sideEffect">memory impairment</ph>; <ph outputclass="sideEffect">paraesthesia</ph>; <ph outputclass="sideEffect">peripheral oedema</ph>; <ph outputclass="sideEffect">polymenorrhoea</ph>; <ph outputclass="sideEffect">polyuria</ph>; <ph outputclass="sideEffect">sleep disturbances</ph>; <ph outputclass="sideEffect">taste disturbances</ph></p>
          </sectiondiv>
          <sectiondiv outputclass="rare">
            <p outputclass="title">Rare</p>
            <p outputclass="sideEffects">
              <ph outputclass="sideEffect">Blood pressure changes</ph>; <ph outputclass="sideEffect">constipation</ph></p>
          </sectiondiv>
          <sectiondiv outputclass="veryRare">
            <p outputclass="title">Very rare</p>
            <p outputclass="sideEffects">
              <ph outputclass="sideEffect">Anorexia</ph>; <ph outputclass="sideEffect">antibiotic-associated colitis</ph>; <ph outputclass="sideEffect">arthralgia</ph>; <ph outputclass="sideEffect">aseptic meningitis</ph>; <ph outputclass="sideEffect">ataxia</ph>; <ph outputclass="sideEffect">blood disorders</ph>; <ph outputclass="sideEffect">convulsions</ph>; <ph outputclass="sideEffect">cough</ph>; <ph outputclass="sideEffect">depression</ph>; <ph outputclass="sideEffect">eosinophilia</ph>; <ph outputclass="sideEffect">glossitis</ph>; <ph outputclass="sideEffect">hallucinations</ph>; <ph outputclass="sideEffect">hepatic necrosis</ph>; <ph outputclass="sideEffect">hypoglycaemia</ph>; <ph outputclass="sideEffect">hyponatraemia</ph>; <ph outputclass="sideEffect">interstitial nephritis</ph>; <ph outputclass="sideEffect">jaundice</ph>; <ph outputclass="sideEffect">leucopenia</ph>; <ph outputclass="sideEffect">liver damage</ph>; <ph outputclass="sideEffect">megaloblastic anaemia</ph>; <ph outputclass="sideEffect">myalgia</ph>; <ph outputclass="sideEffect">myocarditis</ph>; <ph outputclass="sideEffect">pancreatitis</ph>; <ph outputclass="sideEffect">peripheral neuropathy</ph>; <ph outputclass="sideEffect">photosensitivity</ph>; <ph outputclass="sideEffect">pulmonary infiltrates</ph>; <ph outputclass="sideEffect">renal disorders</ph>; <ph outputclass="sideEffect">shortness of breath</ph>; <ph outputclass="sideEffect">Stevens-Johnson syndrome</ph>; <ph outputclass="sideEffect">stomatitis</ph>; <ph outputclass="sideEffect">systemic lupus erythematosus</ph>; <ph outputclass="sideEffect">thrombocytopenia</ph>; <ph outputclass="sideEffect">tinnitus</ph>; <ph outputclass="sideEffect">toxic epidermal necrolysis</ph>; <ph outputclass="sideEffect">uveitis</ph>; <ph outputclass="sideEffect">vasculitis</ph>; <ph outputclass="sideEffect">vertigo</ph></p>
          </sectiondiv>
          <sectiondiv outputclass="notKnown">
            <p outputclass="title">Frequency not known</p>
            <p outputclass="sideEffects">
              <ph outputclass="sideEffect">Vomiting</ph>
            </p>
          </sectiondiv>
        </sectiondiv>
      </section>
      <section outputclass="specificSideEffects">
        <sectiondiv outputclass="frequencies">
          <sectiondiv outputclass="commonOrVeryCommon">
            <p outputclass="title">Common or very common</p>
            <sectiondiv outputclass="sideEffectsWithIndications">
              <p outputclass="title">When used for erectile dysfunction</p>
              <p>
                <ph outputclass="sideEffect">nausea</ph>; <ph outputclass="sideEffect">dizziness</ph>; <ph outputclass="sideEffect">vomiting</ph></p>
            </sectiondiv>
            <sectiondiv outputclass="sideEffectsWithIndications">
              <p outputclass="title">When used for pulmonary arterial hypertension</p>
              <p>
                <ph outputclass="sideEffect">abdominal distension</ph>; <ph outputclass="sideEffect">alopecia</ph>; <ph outputclass="sideEffect">anaemia</ph>; <ph outputclass="sideEffect">anxiety</ph>; <ph outputclass="sideEffect">bronchitis</ph>; <ph outputclass="sideEffect">cellulitis</ph>; <ph outputclass="sideEffect">cough</ph>; <ph outputclass="sideEffect">diarrhoea</ph>; <ph outputclass="sideEffect">dry mouth</ph>; <ph outputclass="sideEffect">epistaxis</ph>; <ph outputclass="sideEffect">fever</ph>; <ph outputclass="sideEffect">gastritis</ph>; <ph outputclass="sideEffect">gastro-oesophageal reflux</ph>; <ph outputclass="sideEffect">haemorrhoids</ph>; <ph outputclass="sideEffect">headache</ph>; <ph outputclass="sideEffect">influenza-like symptoms</ph>; <ph outputclass="sideEffect">insomnia</ph>; <ph outputclass="sideEffect">limb pain</ph>; <ph outputclass="sideEffect">night sweats</ph>; <ph outputclass="sideEffect">oedema</ph>; <ph outputclass="sideEffect">painful red eyes</ph>; <ph outputclass="sideEffect">paraesthesia</ph>; <ph outputclass="sideEffect">photophobia</ph>; <ph outputclass="sideEffect">retinal haemorrhage</ph>; <ph outputclass="sideEffect">tremor</ph>; <ph outputclass="sideEffect">vertigo</ph></p>
            </sectiondiv>
            <sectiondiv outputclass="sideEffectsWithRoutes">
              <p outputclass="title">With intravenous use</p>
              <p>
                <ph outputclass="sideEffect">bronchopulmonary dysplasia</ph> (in neonates); <ph outputclass="sideEffect">fluid retention</ph> (in neonates); <ph outputclass="sideEffect">haematuria</ph> (in neonates); <ph outputclass="sideEffect">hyponatraemia</ph> (in neonates); <ph outputclass="sideEffect">intestinal perforation</ph> (in neonates); <ph outputclass="sideEffect">intraventricular haemorrhage</ph> (in neonates); <ph outputclass="sideEffect">ischaemic brain injury</ph> (in neonates); <ph outputclass="sideEffect">neutropenia</ph> (in neonates); <ph outputclass="sideEffect">oliguria</ph> (in neonates); <ph outputclass="sideEffect">pulmonary haemorrhage</ph> (in neonates); <ph outputclass="sideEffect">thrombocytopenia</ph> (in neonates)</p>
            </sectiondiv>
          </sectiondiv>
          <sectiondiv outputclass="uncommon">
            <p outputclass="title">Uncommon</p>
            <sectiondiv outputclass="sideEffectsWithRoutes">
              <p outputclass="title">With intravenous use</p>
              <p>
                <ph outputclass="sideEffect">gastrointestinal haemorrhage</ph> (in neonates)</p>
            </sectiondiv>
            <sectiondiv outputclass="sideEffectsWithIndications">
              <p outputclass="title">When used for erectile dysfunction</p>
              <p>
                <ph outputclass="sideEffect">chest pain</ph>; <ph outputclass="sideEffect">drowsiness</ph>; <ph outputclass="sideEffect">dry mouth</ph>; <ph outputclass="sideEffect">epistaxis</ph>; <ph outputclass="sideEffect">fatigue</ph>; <ph outputclass="sideEffect">hypertension</ph>; <ph outputclass="sideEffect">hypoaesthesia</ph>; <ph outputclass="sideEffect">hypotension</ph>; <ph outputclass="sideEffect">painful red eyes</ph>; <ph outputclass="sideEffect">palpitation</ph>; <ph outputclass="sideEffect">tachycardia</ph>; <ph outputclass="sideEffect">tinnitus</ph>; <ph outputclass="sideEffect">vertigo</ph></p>
            </sectiondiv>
            <sectiondiv outputclass="sideEffectsWithIndications">
              <p outputclass="title">When used for pulmonary arterial hypertension</p>
              <p>
                <ph outputclass="sideEffect">gynaecomastia</ph>; <ph outputclass="sideEffect">haematuria</ph>; <ph outputclass="sideEffect">penile haemorrhage</ph>; <ph outputclass="sideEffect">priapism</ph></p>
            </sectiondiv>
          </sectiondiv>
          <sectiondiv outputclass="rare">
            <p outputclass="title">Rare</p>
            <sectiondiv outputclass="sideEffectsWithRoutes">
              <p outputclass="title">With oral use</p>
              <p>
                <ph outputclass="sideEffect">alveolitis</ph> (in children); <ph outputclass="sideEffect">aseptic meningitis (patients with connective-tissue disorders such as systemic lupus erythematosus may be especially susceptible)</ph> (in children); <ph outputclass="sideEffect">hepatic damage</ph> (in children); <ph outputclass="sideEffect">interstitial fibrosis associated with NSAIDs can lead to renal failure</ph> (in children); <ph outputclass="sideEffect">pancreatitis</ph> (in children); <ph outputclass="sideEffect">papillary necrosis associated with NSAIDs can lead to renal failure</ph> (in children); <ph outputclass="sideEffect">pulmonary eosinophilia</ph> (in children); <ph outputclass="sideEffect">Stevens-Johnson syndrome</ph> (in children); <ph outputclass="sideEffect">toxic epidermal necrolysis</ph> (in children); <ph outputclass="sideEffect">visual disturbances</ph> (in children)</p>
            </sectiondiv>
            <sectiondiv outputclass="sideEffectsWithRoutes">
              <p outputclass="title">With systemic use</p>
              <p>
                <ph outputclass="sideEffect">alveolitis</ph> (in adults); <ph outputclass="sideEffect">aseptic meningitis (patients with connective-tissue disorders such as systemic lupus erythematosus may be especially susceptible)</ph> (in adults); <ph outputclass="sideEffect">hepatic damage</ph> (in adults); <ph outputclass="sideEffect">interstitial fibrosis associated with NSAIDs can lead to renal failure</ph> (in adults); <ph outputclass="sideEffect">pancreatitis</ph> (in adults); <ph outputclass="sideEffect">papillary necrosis associated with NSAIDs can lead to renal failure</ph> (in adults); <ph outputclass="sideEffect">pulmonary eosinophilia</ph> (in adults); <ph outputclass="sideEffect">Stevens-Johnson syndrome</ph> (in adults); <ph outputclass="sideEffect">toxic epidermal necrolysis</ph> (in adults); <ph outputclass="sideEffect">visual disturbances</ph> (in adults)</p>
            </sectiondiv>
            <sectiondiv outputclass="sideEffectsWithIndications">
              <p outputclass="title">When used for erectile dysfunction</p>
              <p>
                <ph outputclass="sideEffect">atrial fibrillation</ph>; <ph outputclass="sideEffect">cerebrovascular accident</ph>; <ph outputclass="sideEffect">facial oedema</ph>; <ph outputclass="sideEffect">hypersensitivity reactions</ph>; <ph outputclass="sideEffect">priapism</ph>; <ph outputclass="sideEffect">rash</ph>; <ph outputclass="sideEffect">Stevens-Johnson syndrome</ph>; <ph outputclass="sideEffect">syncope</ph></p>
            </sectiondiv>
          </sectiondiv>
          <sectiondiv outputclass="veryRare">
            <p outputclass="title">Very rare</p>
            <sectiondiv outputclass="sideEffectsWithRoutes">
              <p outputclass="title">With oral use</p>
              <p>
                <ph outputclass="sideEffect">pyrexia</ph>
              </p>
            </sectiondiv>
            <sectiondiv outputclass="sideEffectsWithIndications">
              <p outputclass="title">When used for blepharospasm</p>
              <p>
                <ph outputclass="sideEffect">angle-closure glaucoma</ph>; <ph outputclass="sideEffect">corneal epithelial defect</ph>; <ph outputclass="sideEffect">corneal perforation</ph>; <ph outputclass="sideEffect">corneal ulceration</ph></p>
            </sectiondiv>
            <sectiondiv outputclass="sideEffectsWithIndications">
              <p outputclass="title">When used for hemifacial spasm</p>
              <p>
                <ph outputclass="sideEffect">angle-closure glaucoma</ph>; <ph outputclass="sideEffect">corneal epithelial defect</ph>; <ph outputclass="sideEffect">corneal perforation</ph>; <ph outputclass="sideEffect">corneal ulceration</ph></p>
            </sectiondiv>
          </sectiondiv>
          <sectiondiv outputclass="notKnown">
            <p outputclass="title">Frequency not known</p>
            <sectiondiv outputclass="sideEffectsWithRoutes">
              <p outputclass="title">With intravenous use</p>
              <p>
                <ph outputclass="sideEffect">hypoxaemia</ph> (in neonates)</p>
            </sectiondiv>
            <sectiondiv outputclass="sideEffectsWithRoutes">
              <p outputclass="title">With oral use</p>
              <p>
                <ph outputclass="sideEffect">angioedema</ph> (in children); <ph outputclass="sideEffect">blood disorders</ph> (in children); <ph outputclass="sideEffect">bronchospasm</ph> (in children); <ph outputclass="sideEffect">colitis (induction of or exacerbation of)</ph> (in children); <ph outputclass="sideEffect">Crohn’s disease (induction of or exacerbation of)</ph> (in children); <ph outputclass="sideEffect">depression</ph> (in children); <ph outputclass="sideEffect">diarrhoea</ph> (in children); <ph outputclass="sideEffect">dizziness</ph> (in children); <ph outputclass="sideEffect">drowsiness</ph> (in children); <ph outputclass="sideEffect">fluid retention (rarely precipitating congestive heart failure)</ph> (in children); <ph outputclass="sideEffect">gastro-intestinal bleeding</ph> (in children); <ph outputclass="sideEffect">gastro-intestinal discomfort</ph> (in children); <ph outputclass="sideEffect">gastro-intestinal disturbances</ph> (in children); <ph outputclass="sideEffect">gastro-intestinal ulceration</ph> (in children); <ph outputclass="sideEffect">haematuria</ph> (in children); <ph outputclass="sideEffect">headache</ph> (in children); <ph outputclass="sideEffect">hearing disturbances</ph> (in children); <ph outputclass="sideEffect">hypersensitivity reactions</ph> (in children); <ph outputclass="sideEffect">insomnia</ph> (in children); <ph outputclass="sideEffect">nausea</ph> (in children); <ph outputclass="sideEffect">nervousness</ph> (in children); <ph outputclass="sideEffect">photosensitivity</ph> (in children); <ph outputclass="sideEffect">raised blood pressure</ph> (in children); <ph outputclass="sideEffect">rashes</ph> (in children); <ph outputclass="sideEffect">renal failure (especially in patients with pre-existing renal impairment)</ph> (in children); <ph outputclass="sideEffect">tinnitus</ph> (in children); <ph outputclass="sideEffect">vertigo</ph> (in children)</p>
            </sectiondiv>
            <sectiondiv outputclass="sideEffectsWithRoutes">
              <p outputclass="title">With systemic use</p>
              <p>
                <ph outputclass="sideEffect">angioedema</ph> (in adults); <ph outputclass="sideEffect">blood disorders</ph> (in adults); <ph outputclass="sideEffect">bronchospasm</ph> (in adults); <ph outputclass="sideEffect">colitis (induction of or exacerbation of)</ph> (in adults); <ph outputclass="sideEffect">Crohn’s disease (induction of or exacerbation of)</ph> (in adults); <ph outputclass="sideEffect">depression</ph> (in adults); <ph outputclass="sideEffect">diarrhoea</ph> (in adults); <ph outputclass="sideEffect">dizziness</ph> (in adults); <ph outputclass="sideEffect">drowsiness</ph> (in adults); <ph outputclass="sideEffect">fluid retention (rarely precipitating congestive heart failure)</ph> (in adults); <ph outputclass="sideEffect">gastro-intestinal bleeding</ph> (in adults); <ph outputclass="sideEffect">gastro-intestinal discomfort</ph> (in adults); <ph outputclass="sideEffect">gastro-intestinal disturbances</ph> (in adults); <ph outputclass="sideEffect">gastro-intestinal ulceration</ph> (in adults); <ph outputclass="sideEffect">haematuria</ph> (in adults); <ph outputclass="sideEffect">headache</ph> (in adults); <ph outputclass="sideEffect">hearing disturbances</ph> (in adults); <ph outputclass="sideEffect">hypersensitivity reactions</ph> (in adults); <ph outputclass="sideEffect">insomnia</ph> (in adults); <ph outputclass="sideEffect">nausea</ph> (in adults); <ph outputclass="sideEffect">nervousness</ph> (in adults); <ph outputclass="sideEffect">photosensitivity</ph> (in adults); <ph outputclass="sideEffect">raised blood pressure</ph> (in adults); <ph outputclass="sideEffect">rashes</ph> (in adults); <ph outputclass="sideEffect">renal failure (especially in patients with pre-existing renal impairment)</ph> (in adults); <ph outputclass="sideEffect">tinnitus</ph> (in adults); <ph outputclass="sideEffect">vertigo</ph> (in adults)</p>
            </sectiondiv>
            <sectiondiv outputclass="sideEffectsWithRoutes">
              <p outputclass="title">With topical use</p>
              <p>
                <ph outputclass="sideEffect">photosensitivity</ph> (in adults); <ph outputclass="sideEffect">rash (discontinue use if develops)</ph> (in adults)</p>
            </sectiondiv>
            <sectiondiv outputclass="sideEffectsWithIndications">
              <p outputclass="title">When used for erectile dysfunction</p>
              <p>
                <ph outputclass="sideEffect">arrhythmia</ph>; <ph outputclass="sideEffect">myocardial infarction</ph>; <ph outputclass="sideEffect">seizures</ph>; <ph outputclass="sideEffect">unstable angina</ph></p>
            </sectiondiv>
            <sectiondiv outputclass="sideEffectsWithIndications">
              <p outputclass="title">When used for pulmonary arterial hypertension</p>
              <p>
                <ph outputclass="sideEffect">rash</ph>; <ph outputclass="sideEffect">retinal vascular occlusion</ph></p>
            </sectiondiv>
            <sectiondiv outputclass="sideEffectsWithIndications">
              <p outputclass="title">When used for uncomplicated premature labour</p>
              <p>
                <ph outputclass="routesAndIndications">with <ph outputclass="route">intravenous</ph> use for uncomplicated premature labour</ph>
                <ph outputclass="sideEffect">bronchospasm</ph> (in adults); <ph outputclass="sideEffect">muscle tension</ph> (in adults); <ph outputclass="sideEffect">pulmonary oedema</ph> (in adults); <ph outputclass="sideEffect">vomiting</ph> (in adults)</p>
            </sectiondiv>
          </sectiondiv>
        </sectiondiv>
      </section>
      <section outputclass="sideEffectsAdvice">
        <title>Side-effects, further information</title>
        <sectiondiv>
          <p outputclass="title">Serious side-effects</p>
          <p>For information about cardiovascular and gastro-intestinal side-effects, and a possible exacerbation of symptoms in asthma, see <xref format="dita" href="PHP78612.xml" type="bookmark">Non-steroidal anti-inflammatory drugs</xref>.</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">topical</ph> use in adults</p>
          <p>Topical application of large amounts can result in systemic effects, including hypersensitivity and asthma (renal disease has also been reported).</p>
        </sectiondiv>
      </section>
      <section outputclass="sideEffectsOverdosageInformation">
        <title>Overdose</title>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">systemic</ph> use in adults</p>
          <p>Mefenamic acid has important consequences in overdosage because it can cause convulsions, which if prolonged or recurrent, require treatment.</p>
          <p>For details on the management of poisoning, see <xref format="dita" href="PHP78558.xml" type="bookmark">Emergency treatment of poisoning</xref>, in particular, Convulsions.</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">systemic</ph> use in children</p>
          <p>Mefenamic acid has important consequences in overdosage because it can cause convulsions, which if prolonged or recurrent, require treatment with intravenous lorazepam or diazepam.</p>
          <p>For details on the management of poisoning, see <xref format="dita" href="PHP78558.xml" type="bookmark">Emergency treatment of poisoning</xref>, in particular, Convulsions.</p>
        </sectiondiv>
        <sectiondiv>
          <p>Overdosage with ibuprofen may cause nausea, vomiting, epigastric pain, and tinnitus, but more serious toxicity is very uncommon. <xref format="dita" href="PHP182.xml" type="drug">Charcoal, activated</xref> followed by symptomatic measures are indicated if more than 100 mg/kg has been ingested within the preceding hour.</p>
          <p>For details on the management of poisoning, see <xref format="dita" href="PHP78558.xml" type="bookmark">Emergency treatment of poisoning</xref>.</p>
        </sectiondiv>
      </section>
    </body>
  </topic>
  <topic id="PHP47602" outputclass="allergyAndCrossSensitivity" rev="1.12">
    <title>Allergy and cross-sensitivity</title>
    <body>
      <section outputclass="allergyAndCrossSensitivityContraindications">
        <sectiondiv>
          <p>Contraindicated in patients with a history of hypersensitivity to aspirin or any other NSAID—which includes those in whom attacks of asthma, angioedema, urticaria or rhinitis have been precipitated by aspirin or any other NSAID.</p>
        </sectiondiv>
      </section>
      <section outputclass="allergyAndCrossSensitivityCrossSensitivity">
        <sectiondiv>
          <p>Caution if teicoplanin sensitivity.</p>
        </sectiondiv>
      </section>
    </body>
  </topic>
  <topic id="PHP47531" outputclass="conceptionAndContraception">
    <title>Conception and contraception</title>
    <body>
      <section outputclass="generalInformation">
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">systemic</ph> use in adults</p>
          <p>Caution—long-term use of some NSAIDs is associated with reduced female fertility, which is reversible on stopping treatment.</p>
        </sectiondiv>
          <sectiondiv>
            <p>Exclude pregnancy before treatment with cytotoxic drugs.</p>
            <p>Contraceptive advice should be given before cytotoxic therapy begins; manufacturer advises effective contraception before and during treatment.</p>
          </sectiondiv>
          <sectiondiv>
            <p outputclass="specificity">When used for <ph outputclass="indication">Chronic myeloid leaukaemia</ph> or <ph outputclass="indication">Cancer of the cervix</ph></p>
            <p>Regimens that do not contain an alkylating drug or procarbazine may have less effect on fertility, but those with an alkylating drug or procarbazine carry the risk of causing permanent male sterility (there is no effect on potency). Pretreatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause. No increase in fetal abnormalities or abortion rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.</p>
          </sectiondiv>
      </section>
    </body>
  </topic>
  <topic id="PHP47397" outputclass="pregnancy">
    <title>Pregnancy</title>
    <body>
      <section outputclass="doseAdjustments">
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">vaginal</ph> use</p>
          <p>Pregnant women need a longer duration of treatment, usually about 7 days, to clear the infection. Oral antifungal treatment should be avoided during pregnancy.</p>
        </sectiondiv>
      </section>
      <section outputclass="generalInformation">
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">systemic</ph> use</p>
          <p>Avoid unless the potential benefit outweighs the risk.</p>
          <p>Avoid during the third trimester (risk of closure of fetal ductus arteriosus <i>in utero</i> and possibly persistent pulmonary hypertension of the newborn); onset of labour may be delayed and duration may be increased.</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">topical</ph> use in adults</p>
          <p>Patient packs for topical preparations carry a warning to avoid during pregnancy.</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">When used for <ph outputclass="indication">Hypomagnesaemia</ph> or <ph outputclass="indication">Arrhythmias</ph> or <ph outputclass="indication">Prevention of seizures in pre-eclampsia</ph> or <ph outputclass="indication">Treatment of seizures and prevention of seizure recurrence in eclampsia</ph> or <ph outputclass="indication">Severe acute asthma</ph> or <ph outputclass="indication">Continuing respiratory deterioration in anaphylaxis</ph> in adults</p>
          <p>Not known to be harmful for short-term intravenous administration in eclampsia, but excessive doses in third trimester cause neonatal respiratory depression.</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">When used for <ph outputclass="indication">Neonatal hypocalcaemia</ph> or <ph outputclass="indication">Hypomagnesaemia</ph> or <ph outputclass="indication">Torsade de pointes</ph> or <ph outputclass="indication">Severe acute asthma</ph> or <ph outputclass="indication">Continuing respiratory deterioration in anaphylaxis</ph> in children</p>
          <p>Sufficient amount may cross the placenta in mothers treated with high doses e.g. in pre-eclampsia, causing hypotonia and respiratory depression in newborns.</p>
        </sectiondiv>
      </section>
      <section outputclass="additionalMonitoringInPregnancy">
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">systemic</ph> use</p>
          <p>Pregnant women with fluid retention should be monitored closely.</p>
        </sectiondiv>
      </section>
    </body>
  </topic>
  <topic id="PHP47586" outputclass="breastFeeding">
    <title>Breast feeding</title>
    <body>
      <section outputclass="generalInformation">
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">systemic</ph> use in adults</p>
          <p>Use with caution during breast-feeding.</p>
          <p>Amount too small to be harmful but some manufacturers advise avoid (including topical use).</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">oral</ph> use in children</p>
          <p>Use with caution during breast-feeding.</p>
          <p>Amount too small to be harmful but some manufacturers advise avoid.</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">topical</ph> use in adults</p>
          <p>Patient packs for topical preparations carry a warning to avoid during breast-feeding.</p>
        </sectiondiv>
      </section>
      <section outputclass="additionalMonitoringInBreastFeeding">
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">systemic</ph> use</p>
          <p>Infant should be monitored for adrenal suppression if mother is taking a dose higher than 40 mg.</p>
        </sectiondiv>
      </section>
    </body>
  </topic>
  <topic id="PHP47485" outputclass="hepaticImpairment">
    <title>Hepatic impairment</title>
    <body>
      <section outputclass="doseAdjustments">
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">intravenous</ph> use or <ph outputclass="route">oral</ph> use</p>
          <p>Reduce dose.</p>
        </sectiondiv>
      </section>
      <section outputclass="generalInformation">
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">intravenous</ph> use in neonates</p>
          <p>Increased risk of gastro-intestinal bleeding and fluid retention.</p>
          <p>Avoid in severe liver disease.</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">systemic</ph> use in adults</p>
          <p>Use with caution; there is an increased risk of gastro-intestinal bleeding and fluid retention.</p>
          <p>Avoid in severe liver disease.</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">oral</ph> use in children</p>
          <p>Use with caution; there is an increased risk of gastro-intestinal bleeding and fluid retention.</p>
          <p>Avoid in severe liver disease.</p>
        </sectiondiv>
      </section>
      <section outputclass="additionalMonitoringInHepaticImpairment">
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">intravenous</ph> use or <ph outputclass="route">oral</ph> use</p>
          <p>Monitor plasma-chloramphenicol concentration in hepatic impairment.</p>
        </sectiondiv>
      </section>
    </body>
  </topic>
  <topic id="PHP47360" outputclass="renalImpairment">
    <title>Renal impairment</title>
    <body>
      <section outputclass="doseAdjustments">
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">intravenous</ph> use in neonates</p>
          <p>Use lowest effective dose.</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">systemic</ph> use in adults</p>
          <p>The lowest effective dose should be used for the shortest possible duration.</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">oral</ph> use in children</p>
          <p>The lowest effective dose should be used for the shortest possible duration.</p>
        </sectiondiv>
      </section>
      <section outputclass="generalInformation">
        <sectiondiv>
          <p>Use with caution in renal impairment— increased risk of lactic acidosis.</p>
          <sectiondiv>
            <p outputclass="title">Lactic acidosis</p>
            <p>Withdraw or interrupt treatment in those at risk of tissue hypoxia or sudden deterioration in renal function, such as those with dehydration, severe infection, shock, sepsis, acute heart failure, respiratory failure or hepatic impairment, or those who have recently had a myocardial infarction.</p>
          </sectiondiv>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">In adults</p>
          <p>NICE (clinical guideline 87 (May 2009): Type 2 diabetes: The management of type 2 diabetes) recommends that the dose should be reviewed if eGFR less than 45 mL/minute/1.73 m<sup>2</sup> and to avoid if eGFR less than 30 mL/minute/1.73 m<sup>2</sup>.</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">In children</p>
          <p>Avoid in significant renal impairment.</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">intravenous</ph> use in neonates</p>
          <p>Avoid if possible in severe impairment.</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">systemic</ph> use in adults</p>
          <p>Avoid if possible or use with caution.</p>
          <p>Avoid in severe impairment.</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">oral</ph> use in children</p>
          <p>Avoid if possible or use with caution.</p>
          <p>Avoid in severe impairment.</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">topical</ph> use in adults</p>
          <p>Deterioration in renal function has also been reported after topical use.</p>
        </sectiondiv>
      </section>
      <section outputclass="additionalMonitoringInRenalImpairment">
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">systemic</ph> use</p>
          <p>In renal impairment monitor renal function; sodium and water retention may occur and renal function may deteriorate, possibly leading to renal failure.</p>
        </sectiondiv>
      </section>
    </body>
  </topic>
  <topic id="PHP72393" outputclass="monitoringRequirements">
    <title>Monitoring requirements</title>
    <body>
      <section outputclass="patientMonitoringProgrammes">
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">intra-uterine</ph> use</p>
          <p>Gynaecological examination before insertion, 4–6 weeks after insertion, then annually.</p>
        </sectiondiv>
      </section>
      <section outputclass="therapeuticDrugMonitoring">
        <sectiondiv>
          <p>All patients require plasma-vancomycin measurement (after 3 or 4 doses if renal function normal, earlier if renal impairment).</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">intravenous</ph> use</p>
          <p>Pre-dose (‘trough’) concentration should be 10–15 mg/litre (15–20 mg/litre for endocarditis or less sensitive strains of meticillin-resistant <ph outputclass="organism"><i>Staphylococcus aureus</i></ph> or for complicated infections caused by <ph outputclass="organism"><i>S. aureus</i></ph>). An initial loading dose, by intravenous infusion, may be considered—consult local guidelines.</p>
        </sectiondiv>
      </section>
      <section outputclass="monitoringOfPatientParameters">
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">intravenous</ph> use in neonates</p>
          <p>Monitor for bleeding.</p>
          <p>Monitor gastro-intestinal function.</p>
        </sectiondiv>
        <sectiondiv>
          <p>In view of reports of blood dyscrasias (including fatalities) and liver cirrhosis with low-dose methotrexate patients should:</p>
          <ul>
            <li>have full blood count and renal and liver function tests repeated every 1–2 weeks until therapy stabilised, thereafter patients should be monitored every 2–3 months.</li>
            <li>be advised to report all symptoms and signs suggestive of infection, especially sore throat<p>Local protocols for frequency of monitoring may vary.</p><p>Treatment with folinic acid (as calcium folinate) may be required in acute toxicity.</p></li>
          </ul>
        </sectiondiv>
      </section>
    </body>
  </topic>
  <topic id="PHP60842" outputclass="prescribingAndDispensingInformation" rev="1.29">
    <title>Prescribing and dispensing information</title>
    <body>
      <section>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">oral</ph> use</p>
          <p>Flavours of syrup may include orange.</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">topical</ph> use in children</p>
          <p>Caution—topical preparations not generally suitable for children.</p>
        </sectiondiv>
        <sectiondiv>
          <p>Not recommended for diarrhoea associated with invasive organisms such as <ph outputclass="organism"><i>Campylobacter</i></ph> and <ph outputclass="organism"><i>Shigella</i></ph>.</p>
        </sectiondiv>
      </section>
    </body>
  </topic>
  <topic id="PHP58801" outputclass="treatmentCessation" rev="1.15">
    <title>Treatment cessation</title>
    <body>
      <section>
        <sectiondiv>
          <p outputclass="specificity">When used for <ph outputclass="indication">Pulmonary arterial hypertension</ph></p>
          <p>Consider gradual withdrawal.</p>
        </sectiondiv>
      </section>
    </body>
  </topic>
  <topic id="PHP47383" outputclass="patientAndCarerAdvice" rev="1.22">
    <title>Patient and carer advice</title>
    <body>
      <section outputclass="patientResources">
        <sectiondiv>
          <p outputclass="specificity">In children</p>
          <p outputclass="title">Medicines for Children leaflet: Ibuprofen for pain and inflammation</p>
          <p>
            <xref format="html" href="http://www.medicinesforchildren.org.uk/ibuprofen-for-pain-and-inflammation">www.medicinesforchildren.org.uk/ibuprofen-for-pain-and-inflammation</xref>
          </p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="title">Methotrexate treatment booklets</p>
          <p>Methotrexate treatment booklets should be issued where appropriate.</p>
          <p>In <b>England</b>, <b>Wales</b>, and <b>Northern Ireland</b>, they are available for purchase from:</p>
          <ul outputclass="organization">
            <li outputclass="thoroughfare">Gorse Street, Chadderton</li>
            <li outputclass="localityname">Oldham</li>
            <li outputclass="postalcode">OL9 9QH</li>
            <li outputclass="contactnumber">Tel: 0845 610 1112</li>
          </ul>
          <p>GP practices can obtain supplies through their Local Area Team stores. </p>
          <p>NHS Hospitals can order supplies from <xref format="html" href="http://www.nhsforms.co.uk">www.nhsforms.co.uk</xref></p>
          <p>or by emailing nhsforms@mmm.com.</p>
          <p>In <b>Scotland</b>, treatment booklets can be obtained by emailing stockorders.dppas@theapsgroup.com or by fax on 0131 629 9967.</p>
          <p>These booklets include advice for adults taking oral methotrexate for inflammatory conditions, and a section for recording results of blood tests and dosage information.</p>
        </sectiondiv>
      </section>
      <section outputclass="generalPatientAdvice">
        <sectiondiv>
          <p>Patients should be advised to avoid self-medication with over-the-counter aspirin or ibuprofen.</p>
          <p>Patients should be counselled on the dose, treatment booklet, and the use of NSAIDs.</p>
        </sectiondiv>
        <sectiondiv>
          <p>Patients and their carers should be warned to report immediately the onset of any feature of blood disorders (e.g. sore throat, bruising, and mouth ulcers), liver toxicity (e.g. nausea, vomiting, abdominal discomfort and dark urine), and respiratory effects (e.g. shortness of breath).</p>
        </sectiondiv>
      </section>
      <section outputclass="adviceAroundMissedDoses">
        <title>Missed doses</title>
        <sectiondiv>
          <p>When used as an oral contraceptive, the following advice is recommended ‘If you forget a pill, take it as soon as you remember and carry on with the next pill at the right time. If the pill was more than 3 hours overdue you are not protected. Continue normal pill-taking but you must also use another method, such as the condom, for the next 2 days’.</p>
          <p>The Faculty of Sexual and Reproductive Healthcare recommends emergency contraception if one or more progestogen-only contraceptive tablets are missed or taken more than 3 hours late and unprotected intercourse has occurred before 2 further tablets have been correctly taken.</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">intramuscular</ph> use</p>
          <p>For missed doses see product literature.</p>
        </sectiondiv>
      </section>
      <section outputclass="adviceAroundDrivingAndOtherTasks">
        <title>Driving and skilled tasks</title>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">oral</ph> use</p>
          <p>Dizziness and somnolence may affect the performance of skilled tasks (e.g. driving).</p>
        </sectiondiv>
      </section>
      <section outputclass="generalPatientAdvice">
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">topical</ph> use in adults</p>
          <p>For topical preparations, patients and their carers should be advised to wash hands immediately after use.</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">topical</ph> use in adults</p>
          <p outputclass="title">Photosensitivity</p>
          <p>For topical preparations, patients or their carers should be advised against excessive exposure to sunlight of area treated in order to avoid possibility of photosensitivity.</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="title">Diarrhoea and vomiting with use as an oral contraceptive</p>
          <p>Vomiting and persistent, severe diarrhoea can interfere with the absorption of oral progestogen-only contraceptives. If vomiting occurs within 2 hours of taking an oral progestogen-only contraceptive, another pill should be taken as soon as possible. If a replacement pill is not taken within 3 hours of the normal time for taking the progestogen-only pill, or in cases of persistent vomiting or very severe diarrhoea, additional precautions should be used during illness and for 2 days after recovery.</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">oral</ph> use for <ph outputclass="indication">Contraception</ph></p>
          <p outputclass="title">Starting routine</p>
          <p>One tablet daily, on a continuous basis, starting on day 1 of cycle and taken at the same time each day (if delayed by longer than 3 hours contraceptive protection may be lost). Additional contraceptive precautions are not necessary when initiating treatment.</p>
          <sectiondiv>
            <p outputclass="title">Changing from a combined oral contraceptive</p>
            <p>Start on the day following completion of the combined oral contraceptive course without a break (or in the case of ED tablets omitting the inactive ones).</p>
          </sectiondiv>
          <sectiondiv>
            <p outputclass="title">After childbirth</p>
            <p>Oral progestogen-only contraceptives can be started up to and including day 21 postpartum without the need for additional contraceptive precautions. If started more than 21 days postpartum, additional contraceptive precautions are required for 2 days.</p>
          </sectiondiv>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">intra-uterine</ph> use</p>
          <p>Counsel women to seek medical attention promptly in case of significant symptoms, especially pain.</p>
          <p>Patient counselling advised.</p>
          <p>Patient information leaflet to be provided.</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">oral</ph> use for <ph outputclass="indication">Emergency contraception</ph></p>
          <p>If vomiting occurs within 2 hours of taking levonorgestrel, a replacement dose should be given.</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">oral</ph> use for <ph outputclass="indication">Emergency contraception</ph></p>
          <ul>
            <li>When prescribing or supplying hormonal emergency contraception, women should be advised:</li>
            <li>that their next period may be early or late;</li>
            <li>that a barrier method of contraception needs to be used until the next period;</li>
            <li>to seek medical attention promptly if any lower abdominal pain occurs because this could signify an ectopic pregnancy;</li>
            <li>to return in 3 to 4 weeks if the subsequent menstrual bleed is abnormally light, heavy or brief, or is absent, or if she is otherwise concerned (if there is any doubt as to whether menstruation has occurred, a pregnancy test should be performed at least 3 weeks after unprotected intercourse).</li>
          </ul>
        </sectiondiv>
      </section>
      <section outputclass="patientAdviceInPregnancy">
        <sectiondiv>
          <p>Counselling advised on pregnancy.</p>
        </sectiondiv>
      </section>
      <section outputclass="patientAdviceInConceptionAndContraception">
        <title>Patient advice required around conception and contraception</title>
        <sectiondiv>
          <p>Patients planning to conceive should be warned that there is a risk of multiple pregnancy (<i>rarely</i> more than twins).</p>
        </sectiondiv>
      </section>
    </body>
  </topic>
  <topic id="PHP47285" outputclass="professionSpecificInformation" rev="1.17">
    <title>Profession specific information</title>
    <body>
      <section outputclass="dentalPractitionersFormulary">
        <title>Dental practitioners' formulary</title>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">oral</ph> use</p>
          <p>Ibuprofen Oral Suspension Sugar-free may be prescribed.</p>
          <p>Ibuprofen Tablets may be prescribed.</p>
        </sectiondiv>
      </section>
      <section outputclass="adviceForDentalPractitioners">
        <title>Dental information</title>
        <sectiondiv>
          <p>A variety of lidocaine injections with adrenaline is available in dental cartridges.</p>
          <p>Consult expert dental sources for specific advice in relation to dose of lidocaine for dental anaesthesia.</p>
        </sectiondiv>
      </section>
    </body>
  </topic>
  <topic id="PHP64201" outputclass="nationalFunding" rev="1.14">
    <title>National funding/access decisions</title>
    <body>
      <section outputclass="nonNHS">
        <title>NHS restrictions</title>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">topical</ph> use for <ph outputclass="indication">Fungal skin infections</ph></p>
          <p>Ketoconazole cream is not prescribable on the NHS except for seborrhoeic dermatitis and pityriasis versicolor and endorsed 'SLS'.</p>
        </sectiondiv>
      </section>
      <section>
        <sectiondiv outputclass="niceTechnologyAppraisals">
          <p outputclass="title">NICE technology appraisals (TAs)</p>
          <sectiondiv outputclass="niceTechnologyAppraisal">
            <p outputclass="fundingIdentifier">NICE TA337</p>
            <sectiondiv>
              <p outputclass="title">Rifaximin for preventing episodes of overt hepatic encephalopathy (March 2015)</p>
              <p>Rifaximin is recommended, within its marketing authorisation, as an option for reducing the recurrence of episodes of overt hepatic encephalopathy in adults.</p>
            </sectiondiv>
            <xref format="html" href="http://www.nice.org.uk/TA337">www.nice.org.uk/TA337</xref>
          </sectiondiv>
        </sectiondiv>
        <sectiondiv outputclass="niceTechnologyAppraisals">
          <p outputclass="title">NICE technology appraisals (TAs)</p>
          <sectiondiv outputclass="niceTechnologyAppraisal">
            <p outputclass="fundingIdentifier">NICE TA276</p>
            <sectiondiv>
              <p outputclass="specificity">When used by <ph outputclass="route">inhalation</ph></p>
              <p outputclass="title">Tobramycin by dry powder inhalation for pseudomonal lung infection in cystic fibrosis (March 2013)</p>
              <p>Tobramycin dry powder for inhalation is recommended for chronic pulmonary infection caused by <ph outputclass="organism"><i>Pseudomonas aeruginosa</i></ph> in patients with cystic fibrosis only if there is an inadequate response to colistimethate sodium, or if colistimethate sodium cannot be used because of contra-indications or intolerance. The manufacturer must provide tobramycin dry powder for inhalation at the discount agreed as part of the patient access scheme to primary, secondary and tertiary care in the NHS.</p>
              <p>Patients currently receiving tobramycin dry powder for inhalation can continue treatment until they and their clinician consider it appropriate to stop.</p>
            </sectiondiv>
            <xref format="html" href="http://www.nice.org.uk/TA276">www.nice.org.uk/TA276</xref>
          </sectiondiv>
        </sectiondiv>
        <sectiondiv outputclass="smcDecisions">
          <p outputclass="title">Scottish Medicines Consortium (SMC) Decisions</p>
          <sectiondiv outputclass="smcDecision">
            <sectiondiv>
              <p>The <i>Scottish Medicines Consortium</i> has advised (February 2011) that dalteparin (<i>Fragmin</i><ph outputclass="sc"><tm tmtype="reg" /></ph>) is accepted for restricted use within NHS Scotland as extended treatment of symptomatic venous thromboembolism and prevention of its recurrence in patients with solid tumours.</p>
            </sectiondiv>
          </sectiondiv>
        </sectiondiv>
        <sectiondiv outputclass="smcDecisions">
          <p outputclass="title">Scottish Medicines Consortium (SMC) Decisions</p>
          <sectiondiv outputclass="smcDecision">
            <sectiondiv>
              <p outputclass="specificity">When used by <ph outputclass="route">inhalation</ph></p>
              <p>The <i>Scottish Medicines Consortium</i> has advised (March 2014) that fluticasone furoate/vilanterol (<i>Relvar Ellipta</i><tm tmtype="reg" />) is accepted for restricted use within NHS Scotland in patients with severe chronic obstructive pulmonary disease with a forced expiratory volume in 1 second (FEV<sub>1</sub>) less than 50% of the predicted normal value.</p>
            </sectiondiv>
          </sectiondiv>
        </sectiondiv>
      </section>
    </body>
  </topic>
  <topic id="PHP47272" outputclass="exceptionsToLegalCategory" rev="1.15">
    <title>Exceptions to legal category</title>
    <body>
      <section>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">topical</ph> use in adults</p>
          <p>Smaller pack sizes of gel preparations may be available on sale to the public.</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">oral</ph> use</p>
          <p>Azithromycin tablets can be sold to the public for the treatment of confirmed, asymptomatic <ph outputclass="organism"><i>Chlamydia trachomatis</i></ph> genital infection in those over 16 years of age, and for the epidemiological treatment of their sexual partners, subject to maximum single dose of 1 g, maximum daily dose 1 g, and a pack size of 1 g.</p>
        </sectiondiv>
        <sectiondiv>
          <p>
            <i>Levonelle</i>
            <tm tmtype="reg" />
            <i>One Step</i> can be sold to women over 16 years; when supplying emergency contraception to the public, pharmacists should refer to guidance issued by the Royal Pharmaceutical Society.</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">topical</ph> use for <ph outputclass="indication">Fungal skin infections</ph> in adults</p>
          <p>A 15-g tube is available for sale to the public for the treatment of tinea pedis, tinea cruris, and candidal intertrigo.</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">topical</ph> use for <ph outputclass="indication">Seborrhoeic dermatitis and dandruff</ph></p>
          <p>Can be sold to the public for the prevention and treatment of dandruff and seborrhoeic dermatitis of the scalp as a shampoo formulation containing ketoconazole maximum 2%, in a pack containing maximum 120 mL and labelled to show a maximum frequency of application of once every 3 days.</p>
        </sectiondiv>
      </section>
    </body>
  </topic>
  <topic id="PHP41817" outputclass="preTreatmentScreening" rev="1.11">
    <title>Pre-treatment screening</title>
    <body>
      <section>
        <sectiondiv>
          <p outputclass="specificity">When used by <ph outputclass="route">inhalation</ph></p>
          <p>Patients must be assessed for bronchial hyperresponsiveness to inhaled mannitol before starting the therapeutic dose regimen; an initiation dose assessment must be carried out under medical supervision—for details of the initiation dose regimen, consult product literature.</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">intravenous</ph> use</p>
          <p>Assess cardiac function before treatment.</p>
        </sectiondiv>
      </section>
    </body>
  </topic>
  <topic id="PHP69402" outputclass="effectOnLaboratoryTests" rev="1.12">
    <title>Effect on laboratory tests</title>
    <body>
      <section>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">topical</ph> use</p>
          <p>May interfere with thyroid function tests.</p>
        </sectiondiv>
      </section>
    </body>
  </topic>
  <topic id="PHP58881" outputclass="handlingAndStorage" rev="1.8">
    <title>Handling and storage</title>
    <body>
      <section>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">topical</ph> use</p>
          <p>Wash hands immediately after use (or wash hands 30 minutes after application if hands treated).</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">transdermal</ph> use</p>
          <p>Nitrile gloves to be worn while handling patches and cleaning treatment areas (latex gloves do not provide adequate protection).</p>
        </sectiondiv>
      </section>
    </body>
  </topic>
  <topic id="PHP89072" outputclass="lessSuitableForPrescribing" rev="1.18">
    <title>Less suitable for prescribing</title>
    <body>
      <section>
        <sectiondiv>
          <p outputclass="specificity">When used by <ph outputclass="route">eye</ph></p>
          <p>Betamethsone with neomycin eye-drops are less suitable for prescribing.</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">intranasal</ph> use</p>
          <p>Betamethsone with neomycin nasal-drops are less suitable for prescribing; there is no evidence that topical anti-infective nasal preparations have any therapeutic value in rhinitis or sinusitis.</p>
        </sectiondiv>
      </section>
    </body>
  </topic>
  <topic id="PHP6461-medicinalForms" outputclass="medicinalForms">
    <title>Medicinal forms</title>
    <body>
      <section outputclass="licensingVariationStatement">
        <p>There can be variation in the licensing of different medicines containing the same drug.</p>
      </section>

      <p>Forms available from special-order manufacturers include: oral suspension</p>
    </body>
    <xref href="PHP77419.xml" rel="medicinalForm">Tablet</xref>
    <xref href="PHP77372.xml" rel="medicinalForm">Orodispersible tablet</xref>
    <xref href="PHP77359.xml" rel="medicinalForm">Modified-release tablet</xref>
    <xref href="PHP77409.xml" rel="medicinalForm">Capsule</xref>
    <xref href="PHP77385.xml" rel="medicinalForm">Modified-release capsule</xref>
    <xref href="PHP77365.xml" rel="medicinalForm">Effervescent granules</xref>
    <xref href="PHP77413.xml" rel="medicinalForm">Oral suspension</xref>
    <xref href="PHP77400.xml" rel="medicinalForm">Solution for infusion</xref>
    <xref href="PHP77392.xml" rel="medicinalForm">Foam</xref>
    <xref href="PHP77344.xml" rel="medicinalForm">Gel</xref>
    <xref href="PHP77351.xml" rel="medicinalForm">Spray</xref>
    <xref href="PHP77428.xml" rel="medicinalForm">Powder</xref>
  </topic>
</topic>
